Shopping Cart 0
Cart Subtotal
AED 0

Emergent BioSolutions Inc (EBS) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 459

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 918

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 1376
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Emergent BioSolutions Inc (EBS)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Emergent BioSolutions Inc (Emergent) is a life sciences company. It focuses on protecting and enhancing life by providing specialized products to governments and healthcare providers. The company develops specialty products targeting public health threats and emerging infectious diseases. It's product portfolio includes vaccines and antibody therapeutics with focus on infectious diseases, autoimmune diseases and cancer. It uses multiple platform technologies, including the MVAtor and Emergard for delivery of its products. Its marketed products include BioThrax (anthrax vaccine adsorbed); WinRho SDF (Rho(D) immune globulin intravenous; (RSDL) reactive skin decontamination lotion; and HepaGam B for the treatment of hepatitis B. Emergent also has a developmental pipeline of candidates targeting dengue and other influenza infections. The company distributes its products in the US and Canada through its commercial sales forces and third party distributors. Emergent is headquartered in Rockville, Maryland, the US.

Emergent BioSolutions Inc Key Recent Developments

Jun 07,2018: Emergent BioSolutions Announces USD50 Million Expansion of Baltimore Fill/Finish Facility

May 03,2018: Emergent BioSolutions Reports First Quarter 2018 Financial Results

Mar 26,2018: Emergent BioSolutions Announces Executive Management Changes That Enhance Execution of Company's Growth Strategy

Feb 22,2018: Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2017 Financial Results

Jan 08,2018: Emergent BioSolutions Announces Preliminary 2017 Financial Results and Provides 2018 Financial Outlook

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Emergent BioSolutions Inc-Key Facts 6

Emergent BioSolutions Inc-Key Employees 7

Emergent BioSolutions Inc-Key Employee Biographies 8

Emergent BioSolutions Inc-Major Products and Services 10

Emergent BioSolutions Inc-History 11

Emergent BioSolutions Inc-Company Statement 16

Emergent BioSolutions Inc-Locations And Subsidiaries 17

Head Office 17

Other Locations & Subsidiaries 17

Joint Venture 19

Section 2-Company Analysis 20

Company Overview 20

Emergent BioSolutions Inc-Business Description 21

Emergent BioSolutions Inc-Corporate Strategy 22

Emergent BioSolutions Inc-SWOT Analysis 23

SWOT Analysis-Overview 23

Emergent BioSolutions Inc-Strengths 23

Emergent BioSolutions Inc-Weaknesses 24

Emergent BioSolutions Inc-Opportunities 25

Emergent BioSolutions Inc-Threats 26

Emergent BioSolutions Inc-Key Competitors 27

Section 3-Company Financial Ratios 28

Financial Ratios-Capital Market Ratios 28

Financial Ratios-Annual Ratios 29

Performance Chart 32

Financial Performance 32

Financial Ratios-Interim Ratios 33

Financial Ratios-Ratio Charts 34

Section 4-Company's Lifesciences Financial Deals and Alliances 35

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 35

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 37

Emergent BioSolutions Inc, Recent Deals Summary 38

Section 5-Company's Recent Developments 39

Jun 07, 2018: Emergent BioSolutions Announces USD50 Million Expansion of Baltimore Fill/Finish Facility 39

May 03, 2018: Emergent BioSolutions Reports First Quarter 2018 Financial Results 40

Mar 26, 2018: Emergent BioSolutions Announces Executive Management Changes That Enhance Execution of Company's Growth Strategy 43

Feb 22, 2018: Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2017 Financial Results 44

Jan 08, 2018: Emergent BioSolutions Announces Preliminary 2017 Financial Results and Provides 2018 Financial Outlook 47

Nov 02, 2017: Emergent BioSolutions Reports Third Quarter and Nine Months 2017 Financial Results; Raises Calendar Year 2017 Guidance 48

Oct 02, 2017: Emergent BioSolutions Announces Closing of New USD200 Million Senior Secured Credit Facility 51

Sep 18, 2017: HHS partners to develop first intranasal treatment for cyanide poisoning 52

Aug 03, 2017: Emergent BioSolutions Reports Second Quarter and Six Months 2017 Financial Results; Reaffirms Calendar Year 2017 Guidance 53

Jul 31, 2017: Emergent BioSolutions Awarded USD23 Million to Develop Novel Multi-Drug Auto-Injector for U.S. Department of Defense 56

Section 6-Appendix 57

Methodology 57

Ratio Definitions 57

About GlobalData 61

Contact Us 61

Disclaimer 61


List Of Figure

List of Figures

Emergent BioSolutions Inc, Performance Chart (2013-2017) 32

Emergent BioSolutions Inc, Ratio Charts 34

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 35

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 37


List Of Table

List of Tables

Emergent BioSolutions Inc, Key Facts 6

Emergent BioSolutions Inc, Key Employees 7

Emergent BioSolutions Inc, Key Employee Biographies 8

Emergent BioSolutions Inc, Major Products and Services 10

Emergent BioSolutions Inc, History 11

Emergent BioSolutions Inc, Other Locations 17

Emergent BioSolutions Inc, Subsidiaries 17

Emergent BioSolutions Inc, Joint Venture 19

Emergent BioSolutions Inc, Key Competitors 27

Emergent BioSolutions Inc, Ratios based on current share price 28

Emergent BioSolutions Inc, Annual Ratios 29

Emergent BioSolutions Inc, Annual Ratios (Cont...1) 30

Emergent BioSolutions Inc, Annual Ratios (Cont...2) 31

Emergent BioSolutions Inc, Interim Ratios 33

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 35

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 37

Emergent BioSolutions Inc, Recent Deals Summary 38

Currency Codes 57

Capital Market Ratios 57

Equity Ratios 58

Profitability Ratios 58

Cost Ratios 59

Liquidity Ratios 59

Leverage Ratios 60

Efficiency Ratios 60

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Emergent BioSolutions Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Soligenix Inc

PharmAthene Inc

Pfenex Inc

Novartis AG

Mitsubishi Tanabe Pharma Corp

Merck & Co Inc

Intralytix Inc

GlaxoSmithKline Plc

Genentech Inc

Elusys Therapeutics Inc

DynPort Vaccine Company LLC

Crucell NV

Bavarian Nordic A/S

Amgen Inc

Emergent BioSolutions Inc (EBS)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Emergent BioSolutions Inc (Emergent) is a life sciences company. It focuses on protecting and enhancing life by providing specialized products to governments and healthcare providers. The company develops specialty products targeting public health threats and emerging infectious diseases. It's product portfolio includes vaccines and antibody therapeutics with focus on infectious diseases, autoimmune diseases and cancer. It uses multiple platform technologies, including the MVAtor and Emergard for delivery of its products. Its marketed products include BioThrax (anthrax vaccine adsorbed); WinRho SDF (Rho(D) immune globulin intravenous; (RSDL) reactive skin decontamination lotion; and HepaGam B for the treatment of hepatitis B. Emergent also has a developmental pipeline of candidates targeting dengue and other influenza infections. The company distributes its products in the US and Canada through its commercial sales forces and third party distributors. Emergent is headquartered in Rockville, Maryland, the US.

Emergent BioSolutions Inc Key Recent Developments

Jun 07,2018: Emergent BioSolutions Announces USD50 Million Expansion of Baltimore Fill/Finish Facility

May 03,2018: Emergent BioSolutions Reports First Quarter 2018 Financial Results

Mar 26,2018: Emergent BioSolutions Announces Executive Management Changes That Enhance Execution of Company's Growth Strategy

Feb 22,2018: Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2017 Financial Results

Jan 08,2018: Emergent BioSolutions Announces Preliminary 2017 Financial Results and Provides 2018 Financial Outlook

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Emergent BioSolutions Inc-Key Facts 6

Emergent BioSolutions Inc-Key Employees 7

Emergent BioSolutions Inc-Key Employee Biographies 8

Emergent BioSolutions Inc-Major Products and Services 10

Emergent BioSolutions Inc-History 11

Emergent BioSolutions Inc-Company Statement 16

Emergent BioSolutions Inc-Locations And Subsidiaries 17

Head Office 17

Other Locations & Subsidiaries 17

Joint Venture 19

Section 2-Company Analysis 20

Company Overview 20

Emergent BioSolutions Inc-Business Description 21

Emergent BioSolutions Inc-Corporate Strategy 22

Emergent BioSolutions Inc-SWOT Analysis 23

SWOT Analysis-Overview 23

Emergent BioSolutions Inc-Strengths 23

Emergent BioSolutions Inc-Weaknesses 24

Emergent BioSolutions Inc-Opportunities 25

Emergent BioSolutions Inc-Threats 26

Emergent BioSolutions Inc-Key Competitors 27

Section 3-Company Financial Ratios 28

Financial Ratios-Capital Market Ratios 28

Financial Ratios-Annual Ratios 29

Performance Chart 32

Financial Performance 32

Financial Ratios-Interim Ratios 33

Financial Ratios-Ratio Charts 34

Section 4-Company's Lifesciences Financial Deals and Alliances 35

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 35

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 37

Emergent BioSolutions Inc, Recent Deals Summary 38

Section 5-Company's Recent Developments 39

Jun 07, 2018: Emergent BioSolutions Announces USD50 Million Expansion of Baltimore Fill/Finish Facility 39

May 03, 2018: Emergent BioSolutions Reports First Quarter 2018 Financial Results 40

Mar 26, 2018: Emergent BioSolutions Announces Executive Management Changes That Enhance Execution of Company's Growth Strategy 43

Feb 22, 2018: Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2017 Financial Results 44

Jan 08, 2018: Emergent BioSolutions Announces Preliminary 2017 Financial Results and Provides 2018 Financial Outlook 47

Nov 02, 2017: Emergent BioSolutions Reports Third Quarter and Nine Months 2017 Financial Results; Raises Calendar Year 2017 Guidance 48

Oct 02, 2017: Emergent BioSolutions Announces Closing of New USD200 Million Senior Secured Credit Facility 51

Sep 18, 2017: HHS partners to develop first intranasal treatment for cyanide poisoning 52

Aug 03, 2017: Emergent BioSolutions Reports Second Quarter and Six Months 2017 Financial Results; Reaffirms Calendar Year 2017 Guidance 53

Jul 31, 2017: Emergent BioSolutions Awarded USD23 Million to Develop Novel Multi-Drug Auto-Injector for U.S. Department of Defense 56

Section 6-Appendix 57

Methodology 57

Ratio Definitions 57

About GlobalData 61

Contact Us 61

Disclaimer 61


List Of Figure

List of Figures

Emergent BioSolutions Inc, Performance Chart (2013-2017) 32

Emergent BioSolutions Inc, Ratio Charts 34

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 35

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 37


List Of Table

List of Tables

Emergent BioSolutions Inc, Key Facts 6

Emergent BioSolutions Inc, Key Employees 7

Emergent BioSolutions Inc, Key Employee Biographies 8

Emergent BioSolutions Inc, Major Products and Services 10

Emergent BioSolutions Inc, History 11

Emergent BioSolutions Inc, Other Locations 17

Emergent BioSolutions Inc, Subsidiaries 17

Emergent BioSolutions Inc, Joint Venture 19

Emergent BioSolutions Inc, Key Competitors 27

Emergent BioSolutions Inc, Ratios based on current share price 28

Emergent BioSolutions Inc, Annual Ratios 29

Emergent BioSolutions Inc, Annual Ratios (Cont...1) 30

Emergent BioSolutions Inc, Annual Ratios (Cont...2) 31

Emergent BioSolutions Inc, Interim Ratios 33

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 35

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 37

Emergent BioSolutions Inc, Recent Deals Summary 38

Currency Codes 57

Capital Market Ratios 57

Equity Ratios 58

Profitability Ratios 58

Cost Ratios 59

Liquidity Ratios 59

Leverage Ratios 60

Efficiency Ratios 60

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Emergent BioSolutions Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Soligenix Inc

PharmAthene Inc

Pfenex Inc

Novartis AG

Mitsubishi Tanabe Pharma Corp

Merck & Co Inc

Intralytix Inc

GlaxoSmithKline Plc

Genentech Inc

Elusys Therapeutics Inc

DynPort Vaccine Company LLC

Crucell NV

Bavarian Nordic A/S

Amgen Inc